Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership
Clover Health (NASDAQ: CLOV) reported strong Q3 2024 results with significant improvements in financial performance. Insurance revenue grew 7% year-over-year to $322.6 million in Q3, and 9% to $1.0 billion year-to-date. The company reduced its GAAP Net loss from continuing operations to $8.8 million from $33.6 million in Q3 2023, while Adjusted EBITDA increased to $19.3 million from $2.7 million. Insurance BER improved to 82.8% in Q3 2024. Based on strong performance, Clover Health raised its full-year 2024 Adjusted EBITDA guidance to $55-65 million.
Clover Health (NASDAQ: CLOV) ha riportato risultati promettenti per il terzo trimestre del 2024, con significativi miglioramenti nelle performance finanziarie. I ricavi assicurativi sono aumentati del 7% su base annua, raggiungendo i 322,6 milioni di dollari nel terzo trimestre, e del 9% a 1,0 miliardo di dollari da inizio anno. L'azienda ha ridotto la sua perdita netta GAAP da operazioni continuative a 8,8 milioni di dollari, rispetto ai 33,6 milioni di dollari nel terzo trimestre del 2023, mentre l'EBITDA rettificato è aumentato a 19,3 milioni di dollari, rispetto ai 2,7 milioni di dollari precedenti. Il BER assicurativo è migliorato fino all'82,8% nel terzo trimestre del 2024. Sulla base delle solide performance, Clover Health ha rialzato le sue previsioni di EBITDA rettificato per l'intero anno 2024 a 55-65 milioni di dollari.
Clover Health (NASDAQ: CLOV) reportó resultados fuertes para el tercer trimestre de 2024, con mejoras significativas en el desempeño financiero. Los ingresos por seguros crecieron un 7% interanual, alcanzando los 322,6 millones de dólares en el tercer trimestre, y un 9% hasta 1,0 mil millones de dólares en lo que va del año. La compañía redujo su pérdida neta GAAP de operaciones continuas a 8,8 millones de dólares desde los 33,6 millones de dólares en el tercer trimestre de 2023, mientras que el EBITDA ajustado aumentó a 19,3 millones de dólares desde los 2,7 millones de dólares anteriores. El BER de seguros mejoró hasta el 82,8% en el tercer trimestre de 2024. Basándose en un rendimiento sólido, Clover Health elevó su guía de EBITDA ajustado para todo el año 2024 a 55-65 millones de dólares.
Clover Health (NASDAQ: CLOV)는 2024년 3분기 강력한 실적을 보고하며 재무 성과에 상당한 개선을 보였습니다. 보험 수익은 전년 대비 7% 증가하여 3분기 3억 2,260만 달러에 이르렀고, 올해 누적 기준으로는 9% 증가한 10억 달러에 도달했습니다. 회사는 지속적인 운영에서 GAAP 순손실을 3억 3,360만 달러에서 8,800만 달러로 줄였고, 조정된 EBITDA는 270만 달러에서 1,930만 달러로 증가했습니다. 보험 BER은 2024년 3분기 82.8%로 개선되었습니다. 우수한 성과를 바탕으로 Clover Health는 2024년 전체 연도 조정된 EBITDA 가이던스를 5,500만~6,500만 달러로 상향 조정했습니다.
Clover Health (NASDAQ: CLOV) a annoncé de solides résultats pour le troisième trimestre de 2024, avec des améliorations significatives de sa performance financière. Les revenus d'assurance ont augmenté de 7 % par rapport à l'année précédente, atteignant 322,6 millions de dollars au troisième trimestre, et de 9 % à 1,0 milliard de dollars depuis le début de l'année. L'entreprise a réduit sa perte nette GAAP provenant des opérations continues à 8,8 millions de dollars, contre 33,6 millions de dollars au troisième trimestre 2023, tandis que l'EBITDA ajusté a augmenté à 19,3 millions de dollars, contre 2,7 millions de dollars précédemment. Le BER d'assurance s'est amélioré à 82,8 % au troisième trimestre 2024. Sur la base de cette solide performance, Clover Health a révisé à la hausse ses prévisions d'EBITDA ajusté pour l'année 2024 à 55-65 millions de dollars.
Clover Health (NASDAQ: CLOV) berichtet über starke Ergebnisse im dritten Quartal 2024 mit erheblichen Verbesserungen der finanziellen Leistung. Die Versicherungseinnahmen stiegen im Vergleich zum Vorjahr um 7% auf 322,6 Millionen Dollar im dritten Quartal und um 9% auf 1,0 Milliarde Dollar im bisherigen Jahresverlauf. Das Unternehmen verringerte seinen GAAP-Nettoverlust aus fortgeführten Betrieben auf 8,8 Millionen Dollar, verglichen mit 33,6 Millionen Dollar im dritten Quartal 2023, während das bereinigte EBITDA auf 19,3 Millionen Dollar von zuvor 2,7 Millionen Dollar anstieg. Der Versicherungs-BER verbesserte sich im dritten Quartal 2024 auf 82,8%. Basierend auf der starken Leistung hob Clover Health die Prognose für das bereinigte EBITDA für das gesamte Jahr 2024 auf 55-65 Millionen Dollar an.
- Insurance revenue grew 7.1% YoY to $322.6M in Q3 2024
- Adjusted EBITDA improved significantly to $19.3M from $2.7M YoY
- Net loss from continuing operations reduced by 73.8% to $8.8M
- Insurance BER improved by 50 basis points to 82.8%
- Raised full-year 2024 Adjusted EBITDA guidance to $55-65M
- Total cash, equivalents, and investments decreased 20.9% to $531.4M
- Slight decrease in Insurance members to 81,110 from 81,275 YoY
Insights
Clover Health demonstrates significant financial improvement with
The raised FY2024 Adjusted EBITDA guidance to
The achievement of 4.0 Stars for Clover's flagship PPO plan for payment year 2026 marks a important milestone, potentially enabling higher CMS reimbursements and improved market competitiveness. Their technology-driven approach through Clover Assistant demonstrates effectiveness in disease management and cost control, reflected in the improved BER metrics.
The stable member base of 81,110 members, despite slight YoY decrease, combined with strong retention rates and market-leading HEDIS performance, positions the company well for targeted growth in 2025. The focus on early disease identification and management through their care platform presents a scalable model for sustainable growth in the Medicare Advantage market.
Delivers
Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by
Increases Full-Year 2024 guidance midpoint to target updated range of Adjusted EBITDA profitability of
FRANKLIN, Tenn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the third quarter 2024. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.
"We delivered another strong quarter on all metrics. This demonstrates the strength of our model during a period where other approaches are facing significant headwinds," said Clover Health CEO Andrew Toy. "Underpinned by our ability to use technology to empower any physician on a wide network, our results position us to drive membership growth while maintaining strong underlying financial performance. I am proud that, powered by Clover Assistant, our health plans are anchored on identifying and managing diseases as early as possible to better control the total cost of care. This has also contributed to our market-leading HEDIS performance and achievement of 4.0 Stars for our flagship PPO plan for payment year 2026. We believe this validates our care platform and positions us well to invest in growth in both our core Insurance plans and Counterpart offering."
For the third quarter 2024, GAAP Net loss from continuing operations improved to
"Our differentiated approach continues to drive our underlying financial momentum," said Clover Health CFO Peter Kuipers. "Strong execution during the third quarter drove meaningful Adjusted EBITDA profitability improvement. As a result, we have increased our full-year 2024 Adjusted EBITDA profitability guidance. We believe that our strong financial profile and momentum, combined with continued strong Stars performance for our flagship PPO plan, sets us up well to invest in and return to membership growth in 2025."
Key Company highlights are as follows:
| Dollars in Millions | 3Q24 | 3Q23(1) | Change Between (%) | ||||||||
| Insurance revenue | $ | 322.6 | $ | 301.2 | 7.1 | % | |||||
| Insurance net medical claims incurred | 251.6 | 236.5 | 6.4 | % | |||||||
| Total revenue | 331.0 | 306.0 | 8.2 | % | |||||||
| Insurance MCR | 78.0 | % | 78.5 | % | (50 bps) | ||||||
| Insurance BER(2) | 82.8 | % | 83.3 | % | (50 bps) | ||||||
| Salaries and benefits plus General and administrative expenses ("SG&A")(3) | $ | 90.2 | $ | 101.6 | (11.2) | % | |||||
| Adjusted Salaries and benefits plus General and administrative expenses ("Adjusted SG&A")(4)(5) | 61.9 | 67.5 | (8.3) | % | |||||||
| Net loss from continuing operations | (8.8 | ) | (33.6 | ) | 73.8 | % | |||||
| Adjusted EBITDA(5) | 19.3 | 2.7 | 614.8 | % | |||||||
| Total restricted and unrestricted cash, cash equivalents, and investments | $ | 531.4 | $ | 672.0 | (20.9) | % | |||||
Financial Outlook
For full-year 2024, Clover Health is updating its guidance as follows:
| Current 2024 Guidance | Previous 2024 Guidance | ||
| Insurance revenue | |||
| Insurance MCR | |||
| Insurance BER(5) | |||
| Adjusted SG&A(5) | |||
| Adjusted EBITDA(5) |
1 The results of operations for the Company's former Non-Insurance segment have been reclassified as discontinued operations for all periods presented due to the Company's decision to not participate in the ACO Reach program for the 2024 performance year. Refer to Note 17 - Discontinued Operations within the Company's most recent Form 10-Q for additional information.
2 Insurance Benefits Expense Ratio (“BER”) is a Non-GAAP financial measure. A reconciliation of BER to Insurance Net medical claims incurred, net, the most directly comparable GAAP measure, is provided in a table immediately following the consolidated financial statements below. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A. Beginning in the second quarter 2024, the Company is presenting Insurance BER. Management believes that by adding quality improvement expenses into the Insurance BER calculation, this offers a clearer and more accurate representation of our investment in healthcare quality and member engagement, and more fully captures the cost of maintaining and enhancing the quality of care for our members.
3 Salaries and benefits plus General and administrative expenses ("SG&A") is the sum of Salaries and benefits plus General and administrative expenses presented as the GAAP measure in the condensed consolidated financial statements.
4 Adjusted SG&A (Non-GAAP) and Adjusted EBITDA (Non-GAAP) are Non-GAAP financial measures. Reconciliations of Adjusted SG&A (Non-GAAP) to SG&A and Adjusted EBITDA (Non-GAAP) to Net loss from continuing operations, respectively, the most directly comparable GAAP measures, are provided in the tables immediately following the consolidated financial statements below. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A.
5 Reconciliations of projected Adjusted SG&A (Non-GAAP) to projected SG&A, and projected Adjusted EBITDA (Non-GAAP) to Net loss from continuing operations, the most directly comparable GAAP measures, are not provided because Stock-based compensation, which is excluded from Adjusted SG&A (Non-GAAP) and Adjusted EBITDA (Non-GAAP), cannot be reasonably calculated or predicted at this time without unreasonable efforts. A reconciliation of projected Insurance BER (Non-GAAP) to projected Net medical claims incurred, net, the most directly comparable GAAP measure, is not provided because quality improvements, which are included in Insurance BER (Non-GAAP), cannot be reasonably calculated or predicted at this time without unreasonable efforts. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A.
Lives under Clover Management
| September 30, 2024 | September 30, 2023 | ||
| Insurance members | 81,110 | 81,275 |
Earnings Conference Call Details
Clover Health’s management will host a conference call to discuss its financial results on Wednesday, November 6, at 5:00 PM Eastern Time. To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1789 (for callers outside the U.S.) and enter the conference ID: CLOVQ324. A live audio webcast will also be available online at: https://event.on24.com/wcc/r/4738366/21B4058D29B8D4F0F55BC3BAB4EA9B91 and related presentation materials will be available at Clover Health’s Investor Relations website at investors.cloverhealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link and at Clover Health’s Investor Relations website at investors.cloverhealth.com, and will remain available for approximately 12 months.
Upcoming Investor Events & Conferences
- 2024 UBS Global Healthcare Conference at 5:00 p.m. Eastern Time, November 12, 2024
- Canaccord Genuity 2024 Medical Technology, Diagnostics, and Digital Health Forum, November 21, 2024
- 2024 Virtual BTIG Digital Health Forum, November 25, 2024
- 2024 Citi Global Healthcare Conference at 3:15 p.m. Eastern Time, December 3, 2024
Any live and archived webcasts and presentations associated with the conferences listed above may be accessed on Clover Health’s Investor Relations website at: investors.cloverhealth.com/news-and-events/investor-events-presentations.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding future events and Clover Health's future results of operations, financial condition, market size and opportunity, business strategy and plans, and the factors affecting our performance and our objectives for future operations. Forward-looking statements are not guarantees of future performance and you are cautioned not to place undue reliance on such statements. In some cases, you can identify forward looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "can," "could," "should," "would," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "outlook," "forecast," "guidance," "objective," "plan," "seek," "grow," "if," "continue" or the negative of these words or other similar terms or expressions that concern Clover Health's expectations, strategy, priorities, plans or intentions. Forward-looking statements in this press release include, but are not limited to, the following: statements under "Financial Outlook" and statements regarding expectations relating to potential improvements in Insurance MCR, operating expenses, Adjusted SG&A, Insurance BER, and the number of Clover Health's Insurance members, as well as the statements contained in the quotations of our executive officers, future capital needs and other expectations as to future performance, operations and results (including our updated guidance for full-year 2024). Statements regarding our Adjusted EBITDA profitability are also forward-looking, and are based on our current targets which are preliminary and are derived from our 2024 financial outlook. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by forward-looking statements in this press release. Forward-looking statements involve a number of judgments, risks and uncertainties, including, without limitation, risks related to: our expectations regarding results of operations, financial condition, and cash flows; our expectations regarding the development and management of our Insurance business; our ability to successfully enter new service markets and manage our operations; anticipated trends and challenges in our business and in the markets in which we operate; our ability to effectively manage our beneficiary base and provider network; our ability to maintain and increase adoption and use of Clover Assistant, including the expansion of Clover Assistant for external payors and providers under the brand name Counterpart Assistant; the anticipated benefits associated with the use of Clover Assistant, including our ability to utilize the platform to manage our medical care ratios; our ability to maintain or improve our Star Ratings or otherwise continue to improve the financial performance of our business; our ability to develop new features and functionality that meet market needs and achieve market acceptance; our ability to retain and hire necessary employees and staff our operations appropriately; the timing and amount of certain investments in growth; the outcome of any known and unknown litigation and regulatory proceedings; any current, pending, or future legislation, regulations or policies that could have a negative effect on our revenue and businesses, including rules, regulations, and policies relating to healthcare and Medicare; our ability to maintain, protect, and enhance our intellectual property; general economic conditions and uncertainty; persistent high inflation and interest rates; and geopolitical uncertainty and instability. Additional information concerning these and other risk factors is contained under Item 1A. “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 14, 2024, as such risks may be updated in our subsequent filings with the SEC. The forward-looking statements included in this press release are made as of the date hereof. Except as required by law, Clover Health undertakes no obligation to update any of these forward-looking statements after the date of this press release or to conform these statements to actual results or revised expectations.
About Non-GAAP Financial Measures
We use Non-GAAP measures including Insurance BER, Adjusted EBITDA, Adjusted SG&A, and Adjusted SG&A as a percentage of revenue. These Non-GAAP financial measures are provided to enhance the reader's understanding of Clover Health's past financial performance and our prospects for the future. Clover Health's management team uses these Non-GAAP financial measures in assessing Clover Health's performance, as well as in planning and forecasting future periods. These Non-GAAP financial measures are not computed according to GAAP, and the methods we use to compute them may differ from the methods used by other companies. Non-GAAP financial measures are supplemental to and should not be considered a substitute for financial information presented in accordance with generally accepted accounting principles in the United States ("GAAP") and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Readers are encouraged to review the reconciliations of these Non-GAAP financial measures to the comparable GAAP measures, which are attached to this release, together with other important financial information, including our filings with the SEC, on the Investor Relations page of our website at investors.cloverhealth.com.
For a description of these Non-GAAP financial measures, including the reasons management uses each measure, please see Appendix A: "Explanation of Non-GAAP Financial Measures."
The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we aim to extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Visit: www.cloverhealth.com
Investor Relations Contact:
Ryan Schmidt
investors@cloverhealth.com
Press Contact:
Andrew Still-Baxter
press@cloverhealth.com
| CLOVER HEALTH INVESTMENTS, CORP. CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except share amounts) | |||||
| September 30, 2024 (Unaudited) | December 31, 2023 | ||||
| Assets | |||||
| Current assets | |||||
| Cash and cash equivalents | $ | 287,956 | $ | 116,407 | |
| Short-term investments | 1,779 | 12,218 | |||
| Investment securities, available-for-sale (Amortized cost: 2024: | 43,302 | 100,702 | |||
| Investment securities, held-to-maturity (Fair value: 2024: | 15 | 6,902 | |||
| Accrued retrospective premiums | 20,963 | 22,076 | |||
| Other receivables | 14,962 | 16,666 | |||
| Healthcare receivables | 37,314 | 64,164 | |||
| Surety bonds and deposits | 596 | 542 | |||
| Prepaid expenses | 12,949 | 14,418 | |||
| Other assets, current | 2,804 | 1,404 | |||
| Assets related to discontinued operations | 10,087 | 72,471 | |||
| Total current assets | 432,727 | 427,970 | |||
| Investment securities, available-for-sale (Amortized cost: 2024: | 184,085 | 120,208 | |||
| Investment securities, held-to-maturity (Fair value: 2024: | 14,294 | 793 | |||
| Property and equipment, net | 5,336 | 5,082 | |||
| Operating lease right-of-use assets | 2,585 | 3,382 | |||
| Other intangible assets | 2,990 | 2,990 | |||
| Other assets, non-current | 10,996 | 10,246 | |||
| Total assets | $ | 653,013 | $ | 570,671 | |
| CLOVER HEALTH INVESTMENTS, CORP. CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except share amounts) | |||||||
| September 30, 2024 (Unaudited) | December 31, 2023 | ||||||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities | |||||||
| Unpaid claims | $ | 166,070 | $ | 135,737 | |||
| Due to related parties, net | 1,340 | 1,363 | |||||
| Accounts payable and accrued expenses | 25,746 | 37,184 | |||||
| Accrued salaries and benefits | 35,340 | 20,951 | |||||
| Deferred revenue | 17 | 3,099 | |||||
| Operating lease liabilities | 1,345 | 1,665 | |||||
| Other liabilities, current | 836 | 1,017 | |||||
| Liabilities related to discontinued operations | 48,941 | 60,099 | |||||
| Total current liabilities | 279,635 | 261,115 | |||||
| Long-term operating lease liabilities | 2,321 | 2,998 | |||||
| Other liabilities, non-current | 28,891 | 20,164 | |||||
| Total liabilities | 310,847 | 284,277 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity | |||||||
| Class A Common Stock, | 41 | 40 | |||||
| Class B Common Stock, | 9 | 9 | |||||
| Additional paid-in capital | 2,546,167 | 2,461,238 | |||||
| Accumulated other comprehensive loss | 852 | (2,370 | ) | ||||
| Accumulated deficit | (2,180,711 | ) | (2,159,794 | ) | |||
| Less: Treasury stock, at cost; 16,817,010 and 7,912,750 shares held at September 30, 2024 and December 31, 2023, respectively | (24,192 | ) | (12,729 | ) | |||
| Total stockholders' equity | 342,166 | 286,394 | |||||
| Total liabilities and stockholders' equity | $ | 653,013 | $ | 570,671 | |||
| CLOVER HEALTH INVESTMENTS, CORP. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||||||||
| (Unaudited) | |||||||||||||||
| (Dollars in thousands, except per share and share amounts) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenues: | |||||||||||||||
| Premiums earned, net (Net of ceded premiums of | $ | 322,579 | $ | 301,230 | $ | 1,014,201 | $ | 932,699 | |||||||
| Other income | 8,407 | 4,798 | 19,967 | 15,459 | |||||||||||
| Total revenues | 330,986 | 306,028 | 1,034,168 | 948,158 | |||||||||||
| Operating expenses: | |||||||||||||||
| Net medical claims incurred | 249,774 | 235,785 | 763,283 | 754,836 | |||||||||||
| Salaries and benefits | 54,995 | 60,567 | 169,717 | 191,985 | |||||||||||
| General and administrative expenses | 35,201 | 41,030 | 124,194 | 140,384 | |||||||||||
| Premium deficiency reserve expense (benefit) | — | 392 | — | (6,556 | ) | ||||||||||
| Depreciation and amortization | 339 | 557 | 987 | 1,835 | |||||||||||
| Restructuring (recoveries) costs | (538 | ) | 1,313 | 288 | 7,870 | ||||||||||
| Total operating expenses | 339,771 | 339,644 | 1,058,469 | 1,090,354 | |||||||||||
| Loss from continuing operations | (8,785 | ) | (33,616 | ) | (24,301 | ) | (142,196 | ) | |||||||
| Change in fair value of warrants | — | — | 17 | — | |||||||||||
| Interest expense | — | — | — | 7 | |||||||||||
| Loss on investment | — | — | 467 | — | |||||||||||
| Net loss from continuing operations | (8,785 | ) | (33,616 | ) | (24,785 | ) | (142,203 | ) | |||||||
| Net (loss) income from discontinued operations | (370 | ) | (7,853 | ) | 3,868 | (686 | ) | ||||||||
| Net loss | $ | (9,155 | ) | $ | (41,469 | ) | $ | (20,917 | ) | $ | (142,889 | ) | |||
| Per share data: | |||||||||||||||
| Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding | 490,180,103 | 480,770,283 | 488,501,812 | 480,921,520 | |||||||||||
| Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding | 490,180,103 | 480,770,283 | 488,501,812 | 480,921,520 | |||||||||||
| Continuing operations: | |||||||||||||||
| Basic loss per share | $ | (0.02 | ) | $ | (0.07 | ) | $ | (0.05 | ) | $ | (0.30 | ) | |||
| Diluted loss per share | (0.02 | ) | (0.07 | ) | (0.05 | ) | (0.30 | ) | |||||||
| Discontinued operations: | |||||||||||||||
| Basic earnings (loss) per share | 0.00 | (0.02 | ) | 0.01 | 0.00 | ||||||||||
| Diluted earnings (loss) per share | 0.00 | (0.02 | ) | 0.01 | 0.00 | ||||||||||
| Net unrealized gain on available-for-sale investments | 3,111 | 1,643 | 3,222 | 4,302 | |||||||||||
| Comprehensive loss | $ | (6,044 | ) | $ | (39,826 | ) | $ | (17,695 | ) | $ | (138,587 | ) | |||
| Operating Segments | |||||||||||||
| Insurance | Corporate/ Other | Eliminations | Consolidated Total | ||||||||||
| Three Months Ended September 30, 2024 | (in thousands) | ||||||||||||
| Premiums earned, net (Net of ceded premiums of | $ | 322,579 | $ | — | $ | — | $ | 322,579 | |||||
| Other income | 4,314 | 32,422 | (28,329 | ) | 8,407 | ||||||||
| Intersegment revenues | — | 46,944 | (46,944 | ) | — | ||||||||
| Net medical claims incurred | 251,643 | 4,442 | (6,311 | ) | 249,774 | ||||||||
| Gross profit (loss) | $ | 75,250 | $ | 74,924 | $ | (68,962 | ) | $ | 81,212 | ||||
| CLOVER HEALTH INVESTMENTS, CORP. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Dollars in thousands) | |||||||
| Nine Months Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (20,917 | ) | $ | (142,889 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation and amortization expense | 987 | 1,835 | |||||
| Stock-based compensation | 84,686 | 107,795 | |||||
| Change in fair value of warrants and amortization of warrants | 17 | — | |||||
| Accretion, net of amortization | (2,140 | ) | (3,096 | ) | |||
| Accrued interest earned | (354 | ) | — | ||||
| Net realized gains on investment securities | (174 | ) | (20 | ) | |||
| Loss on investment | 467 | — | |||||
| Premium deficiency reserve | — | (6,556 | ) | ||||
| Changes in operating assets and liabilities: | |||||||
| Accrued retrospective premiums | 1,113 | 4,741 | |||||
| Other receivables | 1,704 | 8,836 | |||||
| Surety bonds and deposits | (54 | ) | (17 | ) | |||
| Prepaid expenses | 1,469 | 2,920 | |||||
| Other assets | (2,640 | ) | 5,244 | ||||
| Healthcare receivables | 26,850 | 18,534 | |||||
| Operating lease right-of-use assets | 797 | 405 | |||||
| Unpaid claims | 30,310 | (24,164 | ) | ||||
| Accounts payable and accrued expenses | (11,438 | ) | 2,851 | ||||
| Accrued salaries and benefits | 14,389 | 371 | |||||
| Deferred revenue | (3,082 | ) | 103,295 | ||||
| Other liabilities | 8,546 | 179 | |||||
| Operating lease liabilities | (997 | ) | (900 | ) | |||
| Net cash provided by operating activities from continuing operations | 129,539 | 79,364 | |||||
| Net cash (used in) provided by operating activities from discontinued operations | (8,861 | ) | 34,060 | ||||
| Net cash provided by operating activities | 120,678 | 113,424 | |||||
| Cash flows from investing activities: | |||||||
| Purchases of short-term investments, available-for-sale, and held-to-maturity securities | (153,347 | ) | (142,359 | ) | |||
| Proceeds from sales of short-term investments and available-for-sale securities | 47,804 | 60,436 | |||||
| Proceeds from maturities of short-term investments, available-for-sale, and held-to-maturity securities | 108,788 | 139,122 | |||||
| Purchases of property and equipment | (1,241 | ) | (848 | ) | |||
| Net cash provided by investing activities | 2,004 | 56,351 | |||||
| Cash flows from financing activities: | |||||||
| Issuance of common stock, net of early exercise liability | 243 | 1,149 | |||||
| Repurchases of common stock | (1,772 | ) | — | ||||
| Treasury stock acquired | (9,691 | ) | (5,393 | ) | |||
| Net cash used in financing activities | (11,220 | ) | (4,244 | ) | |||
| Net increase in cash, cash equivalents, and restricted cash for discontinued and continuing operations | 111,462 | 165,531 | |||||
| Cash, cash equivalents, and restricted cash, beginning of period for discontinued and continuing operations | 176,494 | 186,213 | |||||
| Cash, cash equivalents, and restricted cash, end of period for discontinued and continuing operations | $ | 287,956 | $ | 351,744 | |||
| Reconciliation of cash and cash equivalents and restricted cash for discontinued and continuing operations | |||||||
| Cash and cash equivalents | $ | 287,956 | $ | 299,014 | |||
| Restricted cash | — | 52,730 | |||||
| Total cash, cash equivalents, and restricted cash for discontinued and continuing operations | $ | 287,956 | $ | 351,744 | |||
| Supplemental disclosure of non-cash activities | |||||||
| Performance year receivable | $ | — | $ | (185,404 | ) | ||
| Performance year obligation | — | 185,404 | |||||
| CLOVER HEALTH INVESTMENTS, CORP. | |||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | |||||||
| ADJUSTED EBITDA (NON-GAAP) RECONCILIATION | |||||||
| (in thousands)(1) | |||||||
| Three Months Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Net loss from continuing operations (GAAP): | $ | (8,785 | ) | $ | (33,616 | ) | |
| Adjustments | |||||||
| Depreciation and amortization | 339 | 557 | |||||
| Stock-based compensation | 27,988 | 33,070 | |||||
| Premium deficiency reserve expense | — | 392 | |||||
| Restructuring (recoveries) costs | (538 | ) | 1,313 | ||||
| Non-recurring legal expenses and settlements | 259 | 1,007 | |||||
| Adjusted EBITDA (Non-GAAP) | $ | 19,263 | $ | 2,723 | |||
| (1) | The table above includes Non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these Non-GAAP measures, see Appendix A. |
| CLOVER HEALTH INVESTMENTS, CORP. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES ADJUSTED SG&A (NON-GAAP) RECONCILIATION (in thousands)(1) | |||||||
| Three Months Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Salaries and benefits | $ | 54,995 | $ | 60,567 | |||
| General and administrative expenses | 35,201 | 41,030 | |||||
| Total SG&A (GAAP) | 90,196 | 101,597 | |||||
| Adjustments | |||||||
| Stock-based compensation | (27,988 | ) | (33,070 | ) | |||
| Non-recurring legal expenses and settlements | (259 | ) | (1,007 | ) | |||
| Adjusted SG&A (Non-GAAP) | $ | 61,949 | $ | 67,520 | |||
| Total revenues (GAAP) | $ | 330,986 | $ | 306,028 | |||
| Adjusted SG&A (Non-GAAP) as a percentage of revenue | 19 | % | 22 | % | |||
| (1) | The table above includes Non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these Non-GAAP measures, see Appendix A. |
| CLOVER HEALTH INVESTMENTS, CORP. | |||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | |||||||
| INSURANCE BENEFITS EXPENSE RATIO (NON-GAAP) RECONCILIATION | |||||||
| (in thousands)(1) | |||||||
| Three Months Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Net medical claims incurred, net (GAAP): | $ | 251,643 | $ | 236,533 | |||
| Adjustments | |||||||
| Quality improvements | 15,445 | 14,363 | |||||
| Insurance benefits expense, net (Non-GAAP) | $ | 267,088 | $ | 250,896 | |||
| Premiums earned, net (GAAP) | $ | 322,579 | $ | 301,230 | |||
| Insurance benefits expense ratio, net (Non-GAAP) | 82.8 | % | 83.3 | % | |||
| (1) | The table above includes Non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these Non-GAAP measures, see Appendix A. |
CLOVER HEALTH INVESTMENTS, CORP.
Appendix A
Explanation of Non-GAAP Financial Measures
Non-GAAP Definitions
Adjusted EBITDA - A Non-GAAP financial measure defined by us as net loss from continuing operations before depreciation and amortization, loss on investment, stock-based compensation, premium deficiency reserve expense (benefit), restructuring (recoveries) costs, and non-recurring legal expenses and settlements. Adjusted EBITDA is a key measure used by our management team and the board of directors to understand and evaluate our operating performance and trends, to prepare and approve our annual budget and to develop short and long-term operating plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA provide useful measures for period-to-period comparisons of our business. Accordingly, we believe that Adjusted EBITDA provides investors and others useful information to understand and evaluate our operating results in the same manner as our management and our board of directors.
Adjusted SG&A - A Non-GAAP financial measure defined by us as total SG&A less stock-based compensation and non-recurring legal expenses and settlements. We believe that Adjusted SG&A provides management, investors, and others a useful view of our operating spend as it excludes non-cash, stock-based compensation and expenses related to investments that management believes do not reflect the Company's core operating expenses. We believe that Adjusted SG&A as a percentage of revenue is useful to management, investors, and others because it allows us to measure our operational leverage as revenue scales.
Insurance Benefits Expense Ratio - A Non-GAAP financial measure defined by us as benefits expense ratio ("BER"). We calculate our Insurance BER by taking the total of Insurance net medical expenses incurred and quality improvements, and dividing that total by premiums earned on a net basis, in a given period. Quality improvements include expenses associated with activities that improve health outcomes, as defined by the U.S. Department of Health and Human Services ("HHS"), as well as those directly tied to enhancing healthcare quality, such as the Company's spend on health information technology, wellness and prevention programs, initiatives to reduce hospital readmissions, and our clinically focused Member Rewards program. We believe our Insurance BER is useful to management, investors, and others because it offers a clearer and more accurate representation of our investment in healthcare quality and member engagement, and gives a comprehensive view of costs related to maintaining and improving the quality of care of our members, which is crucial for sustaining member satisfaction and adherence to treatment regimens.
FAQ
What was Clover Health's (CLOV) Q3 2024 revenue growth?
What is Clover Health's (CLOV) updated 2024 EBITDA guidance?
How much did Clover Health (CLOV) reduce its net loss in Q3 2024?
